⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2535409 | 0.75 | — | — | |
| SCHEMBL25122085 | 0.70 | GABRR1 (0.32) | — | |
| SCHEMBL13370354 | 0.70 | ABAT (0.39) | — | |
| SCHEMBL1385536 | 0.69 | — | — | |
| SCHEMBL8693124 | 0.69 | — | — | |
| SCHEMBL386786 | 0.69 | — | — | |
| SCHEMBL2539111 | 0.68 | — | — | |
| SCHEMBL7853156 | 0.68 | — | — | |
| SCHEMBL2533565 | 0.67 | — | — | |
| SCHEMBL1435138 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116375549-A | Method and system for synthesizing amide compound from nitrile compound | 深圳湾实验室 | 2023-07-04 | — | — | CN | claimed |
| EP-3998261-A1 | PYRIMIDIN-2-YLAMINO-1H-PYRAZOLS AS LRRK2 INHIBITORS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Denali Therapeutics Inc. (US) | 2022-05-18 | — | — | EP | claimed |
| EP-3472153-A1 | PYRIMIDIN-2-YLAMINO-1H-PYRAZOLS AS LRRK2 INHIBITORS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Denali Therapeutics Inc. (US) | 2019-04-24 | — | — | EP | claimed |
| CN-108640872-A | A kind of GSK-3 inhibitor and the preparation method and application thereof | 山东大学 | 2018-10-12 | — | — | CN | claimed |
| US-20180208582-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2018-07-26 | — | — | US | claimed |
| WO-2017218843-A1 | PYRIMIDIN-2-YLAMINO-1H-PYRAZOLS AS LRRK2 INHIBITORS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS | DENALI THERAPEUTICS INC. (US) | 2017-12-21 | — | — | WO | claimed |
| US-20170362206-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2017-12-21 | — | — | US | claimed |
| US-20090030009-A1 | Heterobicyclic Carboxamides as Inhibitors for Kinases | NOVARTIS AG (CH) | 2009-01-29 | — | — | US | claimed |
| EP-1996578-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | claimed |
| WO-2008009487-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2008-01-24 | — | — | WO | claimed |
| US-11834439-B2 | Compounds, compositions, and methods | DENALI THERAPEUTICS INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230227436-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2023-07-20 | — | — | US | disclosed |
| CN-116375549-A | Method and system for synthesizing amide compound from nitrile compound | 深圳湾实验室 | 2023-07-04 | — | — | CN | disclosed |
| US-20230091225-A1 | Bifunctional chimeric heterocyclic compounds for targeted degradation of androgen receptors and use thereof | HINOVA PHARMACEUTICALS INC. (CN) | 2023-03-23 | — | — | US | disclosed |
| US-11591316-B2 | Compounds, compositions, and methods | DENALI THERAPEUTICS INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | MSD K.K. (JP) | 2006-08-10 | — | — | US | disclosed |
| CN-1812981-A | Heteroaryloxy nitrogenous saturated heterocyclic derivative | BANYU PHARMA CO LTD (JP) | 2006-08-02 | — | — | CN | disclosed |
| US-20060128685-A1 | Pyrazole derivative | DAIICHI PHARMACEUTICAL CO., LTD., (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1642898-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-04-05 | — | — | EP | disclosed |
| EP-1591443-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-02 | — | — | EP | disclosed |